EARLY ACS-TIMI 39

EARLY ACS-(TIMI 39) assessed the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST segment elevation acute coronary syndrome.

MAIN RESULTS:
Early versus delayed, provisional eptifibatide in acute coronary syndromes

PRESENTATIONS

TIMI 39 Slides
Morphine-Clopidogrel Interaction & CV Outcomes in Pts with Non-STEMI ACS in EARLY (Furtado AHA 2018)

PUBLICATIONS

Morphine and Cardiovascular Outcomes Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Angiography

Fasting glucose, NT-proBNP, treatment with eptifibatide, and outcomes in non-ST-segment elevation acute coronary syndromes: An analysis from EARLY ACS

Frequency, Clinical And Angiographic Characteristics, And Outcomes Of High-Risk Non-ST-Segment Elevation Acute Coronary Syndromes Patients With Left Circumflex Culprit Lesions

Prognostic Implications of Low-Level Cardiac Troponin Elevation Using the High-Sensitivity Assay for Cardiac Troponin T: Results from EARLY ACS & SEPIA-TIMI 42

Practice patterns and clinical outcomes among non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients presenting to primary and tertiary hospitals: Insights from the EARLY glycoprotein IIb/IIIa inhibition in NSTE-ACS (EARLY-ACS) trial

Angiographic Outcomes With Early Eptifibatide Therapy in Non-ST-Segment Elevation Acute Coronary Syndrome (from the EARLY ACS Trial)

Association between bleeding and mortality among women and men with high-risk acute coronary syndromes: insights from the Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes (EARLY ACS) trial

Cardiac Troponin after Percutaneous Coronary Intervention and 1-Year Mortality in NSTE ACS Using Systematic Evaluation of Biomarker Trends

Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non-ST-segment elevation acute coronary syndromes patients: An analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome trial

Prevalence and clinical outcomes of undiagnosed diabetes mellitus and prediabetes among patients with high-risk non-ST-segment elevation acute coronary syndrome

Age, treatment, and outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients: Insights from the EARLY ACS trial

Sustained ventricular tachycardia and ventricular fibrillation complicating non-ST-segment-elevation acute coronary syndromes

Association of Hub and Spoke Practice Patterns with Coronary Interventino and Outcomes in Non ST Elevation Acute Coronary Syndromes (NSTE ACS): Insights from the Early Glycoprotein IIb/IIIa Inhibition in NSTE ACS (EARLY-ACS) Trial

Routine Early Eptifibatide, Infarct Size and Outcomes in Non-ST segment Elevation Acute Coronary Syndrome Patients with Elevated Troponins on Admission

Regional patterns of use of a medical management strategy for patients with non-ST-segment elevation acute coronary syndromes: insights from the EARLY ACS Trial

Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal function

Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial

The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome–study design and rationale